Moa Simonsson

Moa Simonsson

Auto-generated profile, based on publicly available information

Moa Simonsson

Department of Medicine Solna, Karolinska Institutet , Stockholm

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in European Heart Journal
Verified
Journal Article
Closed access
MSMoa Simonsson
Moa Simonsson
LWLars Wallentin
Lars Wallentin
JAJoakim Alfredsson
Joakim Alfredsson
DEDavid Erlinge
David Erlinge
KÄKarin Hellström Ängerud
Karin Hellström Ängerud
TJTomas Jernberg
Tomas Jernberg
Aims: To describe the time trends of in-hospital and out-of-hospital bleeding parallel to the development of new treatments and ischaemic outcomes over the last 20 years in a nationwide myocardial infarction (MI) population. Methods and results: Patients with acute MI (n = 371 431) enrolled in the SWEDEHEART registry from 1995 until May 2018 were selected and evaluated for in-hospital bleeding and out-of-hospital bleeding events at 1 year. In-hospital bleeding increased from 0.5% to a peak at 2% 2005/2006 and thereafter slightly decreased to a new plateau around 1.3% by the end of the study period. Out-of-hospital bleeding increased in a stepwise fashion from 2.5% to 3.5 % in the middle of the study period and to 4.8% at the end of the study period. The increase in both in-hospital and out-of-hospital bleeding was parallel to increasing use of invasive strategy and adjunctive antithrombotic treatment, dual antiplatelet therapy (DAPT), and potent DAPT, while the decrease in in-hospital bleeding from 2007 to 2010 was parallel to implementation of bleeding avoidance strategies. In-hospital re-infarction decreased from 2.8% to 0.6% and out-of-hospital MI decreased from 12.6% to 7.1%. The composite out-of-hospital MI, cardiovascular death, and stroke decreased in a similar fashion from 18.4% to 9.1%. Conclusion: During the last 20 years, the introduction of invasive and more intense antithrombotic treatment has been associated with an increase in bleeding events but concomitant there has been a substantial greater reduction of ischaemic events including improved survival.

23 August 2021 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Open access
PDF file
PSPhilip Sarajlic
Philip Sarajlic
MSMoa Simonsson
Moa Simonsson
TJTomas Jernberg
Tomas Jernberg
MBMagnus Bäck
Magnus Bäck
RHRobin Hofmann
Robin Hofmann
Of all spontaneous bleeding complications in patients with acute myocardial infarction (MI), upper gastrointestinal bleeding (UGIB) is common and of specific interest since it could be prevented by several prophylactic measures. We aimed to determine the incidence, associated outcomes, and predictors of UGIB following acute MI. All patients with acute MI enrolled in the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry from January 2007 to June 2016 and discharged alive on any antithrombotic therapy (n = 149 477) were followed regarding UGIB for 1 year. Associated outcomes were determined by Cox proportional hazards regression with UGIB as a time-dependent covariate, adjusting for baseline characteristics, invasive treatment, and medical treatment at discharge. Predictors of UGIB were determined by logistic regression and machine learning models. At 1 year, UGIB had occurred in 2230 patients (cumulative incidence 1.5%) and was significantly associated with an increased risk of all-cause death [hazard ratio (HR) 2.86, 95% confidence interval (CI) 2.58–3.16] and stroke (HR 1.80, 95% CI 1.32–2.45) but not with recurrent MI (HR 1.17, 95% CI 0.97–1.42). The most important predictors of UGIB were haemoglobin, age, systolic blood pressure, blood glucose, smoking status, previous upper gastrointestinal bleeding, and antithrombotic and gastroprotective treatment. After acute MI, readmission because of UGIB is common and significantly associated with poor prognosis. By using machine learning in addition to traditional logistic regression, new predictors of UGIB, such as blood glucose and smoking status, were identified. Incidence, predictors, and associated outcomes following acute myocardial infarction.

10 September 2024 in Circulation
Verified
Journal Article
Closed access
CRChristian Reitan
Christian Reitan
PAPontus Andell
Pontus Andell
JAJoakim Alfredsson
Joakim Alfredsson
DEDavid Erlinge
David Erlinge
RHRobin Hofmann
Robin Hofmann
TJTomas Jernberg
Tomas Jernberg
BACKGROUND: The effect of myocardial infarction (MI) on life expectancy is difficult to study because the prevalence of MI hinders direct comparison with the life expectancy of the general population. We sought to assess this in relation to age, sex, and left ventricular ejection fraction (LVEF) by comparing individuals with MI with matched comparators without previous MI. METHODS: We included patients with a first MI between 1991 and 2022 from the nationwide SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies), each matched with up to 5 comparators on age, sex, and region of residence. Flexible parametric survival models were used to estimate excess mortality and mean loss of life expectancy (LOLE) depending on index year, age, sex, and LVEF, and adjusted for differences in characteristics. RESULTS: A total of 335 748 cases were matched to 1 625 396 comparators. A higher LOLE was observed in younger individuals, women, and those with reduced LVEF (<50%). In 2022, the unadjusted and adjusted mean LOLE spanned from 11.1 and 9.5 years in 50-year-old women with reduced LVEF to 5 and 3.7 months in 80-year-old men with preserved LVEF. Between 1992 and 2022, the adjusted mean LOLE decreased by 36% to 55%: from 4.4 to 2.0 years and from 3.3 to 1.9 years in 50-year-old women and men, respectively, and from 1.7 to 1.0 years and from 1.4 to 0.9 years in 80-year-old women and men, respectively. CONCLUSIONS: LOLE is higher in younger individuals, women, and those with reduced LVEF, but is attenuated when adjusting for comorbidities and risk factors. Advances in MI treatment during the past 30 years have almost halved LOLE, with no clear sign of leveling off to a plateau.

17 October 2025 in The Lancet Digital Health
Verified
Journal Article
Open access
FWFlorian A Wenzl
Florian A Wenzl
KKKlaus F Kofoed
Klaus F Kofoed
MSMoa Simonsson
Moa Simonsson
GAGareth Ambler
Gareth Ambler
NSNiels van der Sangen
Niels van der Sangen
TLThomas F. Lüscher
Thomas F. Lüscher
The Global Registry of Acute Coronary Events (GRACE) scoring system guides the management of patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) according to current guidelines. However, broad validation of the sex-specific GRACE 3.0 in-hospital mortality model, and corresponding models for predicting long-term mortality and the personalised effect of early invasive management, are still needed. We used data of 609 063 patients with NSTE-ACS from ten countries between Jan 1, 2005, and June 24, 2024. A machine learning model for 1-year mortality was developed in 400 054 patients from England, Wales, and Northern Ireland. Both the in-hospital mortality model and the new 1-year mortality model were externally validated in patients from Sweden, Switzerland, Germany, Denmark, Spain, the Netherlands, and Czechia. A separate machine learning model to predict the individualised effect of early versus delayed invasive coronary angiography and revascularisation on a composite primary outcome of all-cause death, non-fatal recurrent myocardial infarction, hospital admission for refractory myocardial ischaemia, or hospital admission for heart failure at a median follow-up of 4·3 years was developed and externally validated in participants from geographically different sets of hospitals in the Danish VERDICT trial. The in-hospital mortality model (area under the receiver operating characteristic curve [AUC] 0·90, 95% CI 0·89-0·91) and the 1-year mortality model (time-dependent AUC 0·84, 95% CI 0·82-0·86) showed excellent discriminative abilities on external validation across all countries. Both models were well calibrated and decision curve analyses suggested favourable clinical utility. Compared with score version 2.0, both models provided improved discrimination and risk reclassification. The individualised treatment effect model effectively identified patients who would benefit from early invasive management on external validation. Patients with high predicted benefit had reduced risk of the composite outcome when randomly assigned to early invasive management (hazard ratio 0·60, 95% CI 0·41-0·88), whereas patients with no-to-moderate predicted benefit did not (1·06, 0·80-1·40; pinteraction=0·014). The individualised treatment effect model suggested that the group of patients with NSTE-ACS who benefit from early intervention might be incompletely captured by current treatment strategies. The updated GRACE 3.0 scoring system provides a validated, practical tool to support personalised risk assessment in patients with NSTE-ACS. Prediction of an individual's long-term cardiovascular benefit from early invasive management could refine future trial design. Swiss Heart Foundation, University of Zurich Foundation, Kurt and Senta Herrmann Foundation, Theodor and Ida Herzog-Egli Foundation, and Foundation for Cardiovascular Research-Zurich Heart House.

29 August 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MSMoa Simonsson
Moa Simonsson
JAJoakim Alfredsson
Joakim Alfredsson
KSKarolina Szummer
Karolina Szummer
TJTomas Jernberg
Tomas Jernberg
PUPeter Ueda
Peter Ueda
Antithrombotic treatment is used to reduce the risk of recurrent ischemic events in patients with acute myocardial infarction (MI). Although most patients receive dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor,1 treatment options for those with concomitant atrial fibrillation/flutter or other indications for oral anticoagulation (OAC) include triple therapy with DAPT and OAC or dual antithrombotic treatment with a single antiplatelet agent and OAC.2 The ischemic risk reduction conferred by these treatments comes at the expense of an increased risk of bleeding. European2 and US3 guidelines therefore recommend individualized antithrombotic therapy based on the patient’s ischemic and bleeding risk.4-6 For example, the duration of DAPT can be prolonged7,8 for patients with high ischemic risk and without high bleeding risk, and DAPT can be shortened or deescalated9,10 for those with a high bleeding risk and lower ischemic risk.11-13

26 May 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Open access
MSMoa Simonsson
Moa Simonsson
MMMoman A Mohammad
Moman A Mohammad
SLSofia Sederholm Lawesson
Sofia Sederholm Lawesson
RHRobin Hofmann
Robin Hofmann
JFJonas Faxén
Jonas Faxén
PAPontus Andell
Pontus Andell
Aims: Acute myocardial infarction (AMI) is associated with significant loss-of-life expectancy, particularly among younger females. Addressing risk factors is crucial for optimizing prevention strategies. The aim of this study was to describe the trends in risk factors and clinical outcomes in a nationwide cohort of young AMI patients stratified by sex. Methods and results: Using Swedish registries, we included AMI patients aged 18–59 and selected five matched non-AMI controls from the general population. Risk factors included hypertension, diabetes, chronic kidney disease, hyperlipidaemia, obesity, smoking and systemic inflammatory disease. Clinical outcomes were major adverse cardiovascular events (death, AMI, stroke, or heart failure) and bleeding events. From 2006 to 2021, 44 254 AMI cases (9602 females and 34 652 males) and 220 721 non-AMI controls (47 967 females and 172 754 males) were included. Among AMI cases, the prevalence of at least one risk factor was higher in females than males (78.9 vs. 73.7%). Obesity increased from 25.2 to 35.5% becoming the most common risk factor. The risk of clinical outcomes was higher in cases than controls and in females compared with males among the cases, but lower among females compared with males among the controls. Five-year mortality was 6.1 vs. 1.3% in females and 4.9 vs. 1.8% males (cases vs. controls). Conclusion: Three in four young AMI patients have at least one known risk factor, of which obesity is the most common. Risk factor burden and clinical outcomes are worse among females. Prevention strategies and enhanced follow-up for young AMI patients should be prioritized. Further studies are needed to investigate sex-specific risk factors.